The Market Is Missing Pozen's Potential Cash Distribution And Upcoming Approval

| About: Pozen, Inc. (POZN)
This article is now exclusive for PRO subscribers.

By Jason Napodano, CFA

Pozen, Inc. (NASDAQ:POZN) has a lot going on right now. The company is preparing for a teleconference with the U.S. FDA relating to its new drug application (NDA) on PA, the company's safer aspirin. The regulatory agency requested the meeting to discuss the existing pharmacology data on the lower-dose PA-81/40 prior to the PDUFA date of January 24, 2014. We are hoping this issue does not derail our thesis that PA-325/40 and PA-81/40 gets approved at that time, but we believe that investors selling stock this week missed a major component of the latest earnings event: management is looking at returning "surplus cash" to shareholders in the form of a distribution, potentially before the end of the year. We struggle to understand how this would impact the stock, but nevertheless still believe in our 'Outperform' rating and $9.00 price target. Below are details from the company's latest earnings call, including why it makes sense for management to follow through on the cash distribution, and we conclude with an options strategy for being involved in POZN.

A Quick Financial Update

On November 6, 2013, Pozen, Inc. reported financial results for the third quarter ended September 30, 2013. Total revenues in the quarter were $2.6 million, and consisted of $1.6 million in royalties from AstraZeneca (NYSE:AZN) on worldwide sales of Vimovo totaling $23 million in the third quarter 2013, and $1 million in ratable recognition of the $15 million upfront payment from Sanofi-Aventis (NYSE:SNY) for the U.S. commercialization rights to the PA franchise struck on September 3, 2013. Pozen is recognizing this $15 million in revenue amortized over a 15-month period. We discuss this transaction in greater detail below.

Operating expenses in the quarter were $7.2 million, significantly higher than expected, but we note included roughly $1.6 million in one-time expenses associated with the Sanofi-Aventis transaction in September. Without this added expense, operating results would have been roughly in line with our forecast. Net loss in the quarter totaled $4.8 million, or $0.16 per share based on 30.5 million shares outstanding. One interesting side note on Pozen, the share count at the end of the third quarter 2003, ten years ago, was 28.4 million. That's some impressive financial stewardship for a small-cap biotech company!

Pozen's press release notes that management is currently focusing its efforts on obtaining FDA approval of PA-81/40 and PA-325/40, which includes transitioning all know-how to Sanofi-Aventis. The company's goals are to complete the remaining Phase 1 study and MAA filing for PA-100/40 in Europe, evaluate the possibility of a MAA filing using existing data for the use of PA in secondary cancer prevention in Europe, attempt to partner all un-partnered assets, and reduce staff and expenses as warranted by business conditions. In this regard, Liz Cermak, the company's Executive Vice President and Chief Commercial Officer will be retiring from Pozen at the end of the year. With PA now being transitioned over to Sanofi-Aventis, Pozen is no longer in need of a Chief Commercial Officer. The press release notes that Ms. Cermak led many facets of the PA program including Pozen's efforts to secure the best agreement possible for shareholders with Sanofi.

Pozen exited the third quarter 2013 with $89.7 million in cash on hand. The company's management team and board of directors are evaluating possible ways of returning value to shareholders, including cash distributions of surplus corporate cash. As Pozen winds down operations post PA approval, we believe the company can reach cash flow positive operations based on the royalties from Vimovo and PA alone. Assuming management has no further desire to bring new candidates into the clinic, we believe the company can dividend as much as $2.00 per share (approximately $60 million in cash) to shareholders. This would still leave them enough to push forward the MAA on PA-100/40 in the EU, as well as explore the possibility of filing an MAA for secondary cancer prevention. We remind investors that Pozen is entitled to $20 million in pre-commercialization milestones on PA from Sanofi-Aventis. On the company's third quarter conference call, CEO John Plachetka would not rule out the possibility of making a decision with respect to a cash distribution before the end of the year 2013. Even after a $60 million distribution, following PA approval, Pozen will still have roughly $45 million in cash.

FDA Requests Teleconference On PA

In the earnings press release, the company noted that,

"As part of Pozen's ongoing interactions and requests for information from the FDA during its review of the NDA for PA-81/40 and PA-325/40, the FDA has requested a teleconference, which has been scheduled for mid-November 2013, to discuss and address the FDA's request for information with respect to the existing clinical pharmacology data on PA-81/40."

On the third quarter call, management noted that they think all the necessary information the FDA would like clarity on is in the NDA filing, but that they need to do a better job in presenting it to the agency. We think the issue stems from a lack of pharmacology data on PA-81/40, not from the actual data itself. For example, the agency is not asking about PA-325/40, the dose in which Pozen conducted all the Phase 2 and 3 studies. Pozen only conducted one bioequivalence study with PA-81/40. CEO John Plachetka noted that these types of pharmacology studies are inexpensive and quick to run, so if the worst-case scenarios arises and the company receives a complete response letter relating to this issue, we think Pozen could be in position to re-file in less than four months at pretty minimal cost. The company plans to provide an update to investors after the teleconference concludes. Although, we note this may include waiting for the minutes from the meeting, which usually takes around one month to receive.

Sanofi-Aventis To Commercialize PA in the U.S.

On September 3, 2013, Pozen Inc. entered into a licensing and collaboration agreement with Sanofi-Aventis for the commercialization of PA-325/40 and PA-81/40 in the U.S. PA-325/40 and PA-81/40 are Pozen's "safer aspirin" products current under U.S. FDA regulatory review with a PDUFA action date scheduled for January 24, 2014. Pozen has been promising a partnership for its PA franchise for over a year now, and it finally delivered with an impressive catch. Partnering with Sanofi-aventis is Pozen's fourth such impressive partnership based on internally-developed combination products. Prior to this licensing and collaboration agreement for PA, Pozen has previously licensed its "safer NSAID" drug, Vimovo, to AstraZeneca, and its dual-action migraine drug, Treximet / MT-400, to GlaxoSmithKline and Johnson & Johnson.

The PA licensing agreement came with $15 million in upfront cash. Pozen is also eligible for $20 million in pre-commercialization milestones, which we assume corresponds to U.S. FDA approval in late January 2014 and the transfer of the NDA to Sanofi (split evenly). Both the upfront and approval milestone were dead-on with our previous predictions on the potential deal. Pozen can earn additional milestone payments upon the achievement of specified sales thresholds for PA, and will receive a double-digit tiered royalty on sales in the U.S. at Sanofi-aventis. The exact terms of the back-end milestones have not been disclosed, only that the royalty rate is tiered between 12.5% and 22.5%. We expect that Pozen should be able to capture an additional $50 million in sales related milestone following commercialization by Sanofi.

Pozen will retain responsibility for obtaining FDA approval for PA. The duo has agreed to share costs up to certain limits with respect to any additional activities that might be required by the FDA to gain final approval for PA. This might include conducting some additional pharmacology work on PA-81/40 depending on how the teleconference with the U.S. FDA goes in the next few weeks. However, at this stage we believe approval in January 2014 seems a good bet considering Pozen completed two positive Phase 3 trials with highly statistically significant data and excellent safety. Both trials were run under a special protocol assessment (SPA) with the U.S. FDA, and Pozen has already been down a similar path gaining approval for Vimovo (formerly called PN-500/20) in April 2010. As noted above, if the agency does request additional work on PA-81/40, we believe Pozen could provide the necessary data in only a few months at a relatively insignificant cost.


In conclusion, we think Pozen's stock is cheap and that the opportunity for a large cash distribution is certainly attractive for investors. However, the FDA teleconference scheduled to take place during the middle of this month is a wildcard event. This could turn out to be a non-issue or something that leads to a relatively minor complete response letter. Either way, we like the stock below $6 and think downside is limited.

One potential way to trade Pozen over the next three months is to buy the stock today at $5.80 and then sell December $6 calls for $0.40. If the FDA teleconference turns out to be no big deal, there's a good chance you get called out at $6.00 in December and walk away earning 11%. If the company distributes $2.00 in cash to investors, you may or may not get called out. Then you keep your shares for the run-up to the PDUFA in late January 2014, plus the options premium of $0.40, and the dividend. If the FDA teleconference turns out to be an issue and management needs to conduct a small pharmacology study to satisfy the FDA's request, we do not think the stock drops that much considering Sanofi is already on board and the delay and cost here will be minimal. Pozen is still on approximately $3 per share in cash to protect downside.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: PropThink is a team of editors, analysts, and writers. This article was written by Jason Napodano, CFA. We did not receive compensation for this article, and we have no business relationship with any company whose stock is mentioned in this article. Use of PropThink’s research is at your own risk. You should do your own research and due diligence before making any investment decision with respect to securities covered herein. You should assume that as of the publication date of any report or letter, PropThink, LLC and persons or entities with whom it has relationships (collectively referred to as "PropThink") has a position in all stocks (and/or options of the stock) covered herein that is consistent with the position set forth in our research report. Following publication of any report or letter, PropThink intends to continue transacting in the securities covered herein, and we may be long, short, or neutral at any time hereafter regardless of our initial recommendation. To the best of our knowledge and belief, all information contained herein is accurate and reliable, and has been obtained from public sources we believe to be accurate and reliable, and not from company insiders or persons who have a relationship with company insiders. Our full disclaimer is available at